Epigenetically Upregulated GEFT-derived Invasion and Metastasis of Rhabdomyosarcoma Via Epithelial Mesenchymal Transition Promoted by the Rac1/Cdc42-PAK Signalling Pathway.
Chunxia Liu,Liang Zhang,Wenwen Cui,Juan Du,Zhenzhen Li,Yuwen Pang,Qianqian Liu,Hao Shang,Lian Meng,Wanyu Li,Lingxie Song,Ping Wang,Yuwen Xie,Yuanyuan Wang,Yang Liu,Jianming Hu,Wenjie Zhang,Feng Li
DOI: https://doi.org/10.1016/j.ebiom.2019.10.060
IF: 11.205
2019-01-01
EBioMedicine
Abstract:Background: Metastasis of rhabdomyosarcoma (RMS) is the primary cause of tumour-related deaths. Previous studies have shown that overexpression of the guanine nucleotide exchange factor T (GEFT) is correlated with a poorer RMS prognosis, but the mechanism remains largely unexplored. Methods: We focused on determining the influence of the GEFT-Rho-GTPase signalling pathway and the epithelial mesenchymal transition (EMT) or mesenchymal epithelial transition (MET) on RMS progression and metastasis by using RMS cell lines, BALB/c nude mice and cells and molecular biology techniques. Findings: GEFT promotes RMS cell viability, migration, and invasion; GEFT also inhibits the apoptosis of RMS cells and accelerates the growth and lung metastasis of RMS by activating the Racl/Cdc42 pathways. Interestingly, GEFT upregulates the expression levels of N-cadherin, Snail, Slug, Twist, Zebl, and Zeb2 and reduces expression level of E-cadherin. Thus, GEFT influences the expression of markers for EMT and MET in RMS cells via the Racl/Cdc42-PAK1 pathways. We also found that the level of GEFT gene promoter methylation in RMS is lower than that in normal striated muscle tissue. Significant differences were observed in the level of GEFT gene methylation in different histological subtypes of RMS. Interpretation: These findings suggest that GEFT accelerates the tumourigenicity and metastasis of RMS by activating Racl/Cdc42-PAK signalling pathway-induced EMT; thus, it may serve as a novel therapeutic target. (C) 2019 The Authors. Published by Elsevier B.V.